Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
AssigneeAbbott Laboratories
InventorsDale J. Kempf, Richard J. Bertz, Jeffrey F. Waring
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
Claims4
A method for treating a disease, disorder, or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate upon administration of atazanavir comprising the step of co-administering ritonavir in an effective amount to a subject in need thereof.
Dependencies are inferred from the claim text.